← All trials
NCT00456092
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2009
- Primary completion
- May 1, 2009
- Completion date
- May 1, 2009
- First posted
- —
- Last posted
- —
- Enrollment
- 204
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- CelgeneLead sponsor
- Newcastle UniversityOverall official - principal investigator
- Radboud UniversityOverall official - principal investigator
- Leiden UniversityOverall official - principal investigator
- Arthritis Program Research Group, OntarioOverall official - principal investigator
- Free University of BerlinOverall official - principal investigator
- Universitaetsklinik KoelnOverall official - principal investigator
- HagaZiekenhuisOverall official - principal investigator
- Haywood Hospital, Stoke on TrentOverall official - principal investigator
- University of HeidelbergOverall official - principal investigator
- University of HamburgOverall official - principal investigator
- University of LeipzigOverall official - principal investigator
- University of LeedsOverall official - principal investigator
- Hasselt UniversityOverall official - principal investigator
- J. W. Goethe UniversityOverall official - principal investigator
- Friedrich Alexander UniversityOverall official - principal investigator
- University of CambridgeOverall official - principal investigator
- University of ManchesterOverall official - principal investigator
- University of TorontoOverall official - principal investigator
- University of LondonOverall official - principal investigator
- CelgeneStudy director
- CHU BrugmannOverall official - principal investigator
- Jan Palfijn HospitalOverall official - principal investigator
- Katholieke Universiteit LeuvenOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.